Heart Failure With Preserved Ejection Fraction Clinical Trial
— E-LUSOfficial title:
Positive Diagnosis of Heart Failure With Preserved LVEF by Exercise Pulmonary Ultrasound.
| NCT number | NCT04644692 |
| Other study ID # | 2020PI156 |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | January 18, 2021 |
| Est. completion date | May 17, 2022 |
| Verified date | March 2023 |
| Source | Central Hospital, Nancy, France |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
The E-LUS study is a prospective, non randomised, monocenter case-control study. The main objective is to evaluate the association of exercise lung ultrasound data acquired during a stress test on a bicycle ergometer with the diagnosis of heart failure with preserved ejection fraction (HFpEF).
| Status | Completed |
| Enrollment | 56 |
| Est. completion date | May 17, 2022 |
| Est. primary completion date | December 21, 2021 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 65 Years and older |
| Eligibility | Inclusion Criteria (Control group) : - Patients 65 years of age and older scheduled for a stress test. - Never diagnosed with either preserved or altered ejection fraction heart failure - Non-dyspneic (New York Heart Association class I) Inclusion Criteria (Case group) : - Patients 65 years of age and older scheduled for a stress test. - Patients already diagnosed with HFpEF following hospitalization for heart failure (LVEF>50%) Exclusion Criteria: - Patients who are opposed to participate to the research project / the use of their data, - Pulmonary or pleural pathology preventing reliable acquisition of lung ultrasound images (e.g. pulmonary fibrosis, diffuse interstitial lung disease or lung cancer) - Patients with a history of thoracic surgery - Patients under legal protection measures (guardianship, curator, judicial safeguard), - Pregnant women, parturient women or nursing mothers, - Patients who are unable to express consent, - Persons deprived of their liberty by a judicial or administrative decision, - Persons subject to psychiatric care, - Patients discharged from hospital for a worsening heart failure hospitalization for less than 15 days |
| Country | Name | City | State |
|---|---|---|---|
| France | CHRU de Nancy | VandÅ“uvre-lès-Nancy |
| Lead Sponsor | Collaborator |
|---|---|
| Central Hospital, Nancy, France |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | The exercise B-lines score measured by the 8-point method. | This score can have a value from 0 to 80, each anterior thoracic measurement point being rated from 0 to 10. A higher value indicate a higher level of pulmonary congestion. The measurement will be taken at the end of the stress test, in the first 2 minutes of recovery | Within 2 minutes after the end of the stress test | |
| Secondary | The diagnosis of HFpEF, as defined by a history of hospitalization for acute heart failure with preserved Left Ventricular Ejection Fraction (LVEF). | For secondary objectives 1, 2, 4, 5, 7 and 8, the endpoint will be the diagnosis of HFpEF, as defined by a history of hospitalization for acute heart failure with preserved LVEF. | Within 10 minutes prior the start of the stress test | |
| Secondary | 2. The delta of B-lines scores during exercise measured by the 8-point method between rest and the end of the exercise | Regarding secondary objective 6, the judgment criterion will be the score of B-lines at rest measured by the 8-point method within 10 minutes prior the start of the stress test. This score can have a value from 0 to 80, each anterior thoracic measurement point being rated from 0 to 10. A higher value indicate a higher level of pulmonary congestion. | Between Within 10 minutes prior the start of the stress test and 2 minutes after the end of the stress test | |
| Secondary | The B-lines score at rest measured by the 8-point method | Within 10 minutes prior the start of the stress test | ||
| Secondary | The modified Borg dyspnea score at rest, during exercise and during recovery. | For secondary objectives 9 and 10, the endpoint will be the modified Borg dyspnea score at rest, during exercise and during recovery. This scale is ranging from 0 to 10, 10 indicating a maximal level of dyspnea. | Within 10 minutes prior the start of the stress test, at the peak of exercise and 3 minutes after the end of the stress test |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Suspended |
NCT05839730 -
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
|
N/A | |
| Recruiting |
NCT05095688 -
Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
|
||
| Recruiting |
NCT06379152 -
Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction
|
||
| Recruiting |
NCT05676684 -
Dapagliflozin, Spironolactone or Both for HFpEF
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04153136 -
Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study)
|
Phase 2 | |
| Recruiting |
NCT06114498 -
Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
|
||
| Recruiting |
NCT05715697 -
Renal Denervation in Patients With Chronic Heart Failure With Preserved Ejection Fraction
|
N/A | |
| Recruiting |
NCT04745013 -
PeRsonalIzed remOtely Guided Preventive exeRcIse Therapy for a healThY Heart
|
N/A | |
| Completed |
NCT05586828 -
A Single-center Retrospective Cohort Study to Explore the Prognostic Significance of CONUT in Elderly CAD Patients With HFpEFand Compare CONUT With Other Objective Nutritional Indices.
|
||
| Completed |
NCT05126836 -
Cilostazol for HFpEF
|
Phase 2 | |
| Recruiting |
NCT04594499 -
The Relationship Between Pericardial Fat Thickness and Arterial Stiffness in HFpEF Patients
|
||
| Active, not recruiting |
NCT05204238 -
Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
|
||
| Completed |
NCT04535726 -
The Relationship Between Blood Pressure and Arterial Stiffness in HFpEF Patients With Different Levels of Obesity
|
||
| Recruiting |
NCT03550235 -
Exploration of Dyspnea at Non-high Brain Natriuretic Peptide (BNP)
|
||
| Completed |
NCT04633460 -
Acute Effects of Exogenous Ketone Ester Administration in Heart Failure
|
Phase 2 | |
| Completed |
NCT06228807 -
Clinical Characteristics and Predictors of Adverse Outcomes in HFpEF
|
||
| Active, not recruiting |
NCT05284617 -
Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF
|
Phase 2 | |
| Recruiting |
NCT05562063 -
Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients
|
Phase 4 | |
| Recruiting |
NCT06027307 -
Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation
|
Phase 3 | |
| Withdrawn |
NCT05322616 -
Single-Ascending Dose Study of JK07 in Subjects With HFpEF
|
Phase 1 |